Knockdown of Med19 Suppresses Proliferation and Enhances Chemo-sensitivity to Cisplatin in Non-small Cell Lung Cancer Cells

  • Wei, Ling (Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute) ;
  • Wang, Xing-Wu (Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute) ;
  • Sun, Ju-Jie (Department of Pathology, Shandong Cancer Hospital and Institute) ;
  • Lv, Li-Yan (Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute) ;
  • Xie, Li (Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute) ;
  • Song, Xian-Rang (Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute)
  • Published : 2015.03.04


Mediator 19 (Med19) is a component of the mediator complex which is a coactivator for DNA-binding factors that activate transcription via RNA polymerase II. Accumulating evidence has shown that Med19 plays important roles in cancer cell proliferation and tumorigenesis. The involvement of Med19 in sensitivity to the chemotherapeutic agent cisplatin was here investigated. We employed RNA interference to reduce Med19 expression in human non-small cell lung cancer (NSCLC) cell lines and analyzed their phenotypic changes. The results showed that after Med19 siRNA transfection, expression of Med19 mRNA and protein was dramatically reduced (p<0.05). Meanwhile, impaired growth potential, arrested cell cycle at G0/G1 phase and enhanced sensitivity to cisplatin were exhibited. Apoptosis and caspase-3 activity were increased when cells were exposed to Med19 siRNA and/or cisplatin. The present findings suggest that Med19 facilitates tumorigenic properties of NSCLC cells and knockdown of Med19 may be a rational therapeutic tool for lung cancer cisplatin sensitization.


Supported by : Natural Science Foundation


  1. Boube M, Joulia L, Cribbs DL, et al (2002). Evidence for a Mediator of RNA polymerase II transcriptional regulation conserved from yeast to man. Cell, 110, 143-51.
  2. Casamassimi A, Napoli C (2007). Mediator complexes and eukaryotic transcription regulation: an overview. Biochimie, 89, 1439-46.
  3. Chen L, Liang Z, Tian Q, et al (2011). Overexpression of LCMR1 is significantly associated with clinical stage in human NSCLC. J Exp Clin Cancer Res, 30, 18.
  4. Conaway JW, Florens L, Sato S, et al (2005). The mammalian Mediator complex. FEBS Lett, 579, 904-8.
  5. Conaway RC, Sato S, Tomomori-Sato C, et al (2005). The mammalian Mediator complex and its role in transcriptional regulation. Trends Biochem Sci, 30, 250-5.
  6. Cui X, Xu D, Lv C, et al (2011). Suppression of MED19 expression by shRNA induces inhibition of cell proliferation and tumorigenesis in human prostate cancer cells. BMB Rep, 44, 547-52.
  7. Fulda S, Debatin KM (2006). Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene, 25, 4798-811.
  8. Galluzzi L, Senovilla L, Vitale I, et al (2012). Molecular mechanisms of cisplatin resistance. Oncogene, 31, 1869-83.
  9. Jang RW, Le Maître A, Ding K, et al (2009). Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the national cancer institute of Canada clinical trials group JBR.10 trial. J Clin Oncol, 27, 4268-73.
  10. Ji-Fu E, Xing JJ, Hao LQ, et al (2012). Suppression of lung cancer metastasis-related protein 1 (LCMR1) inhibits the growth of colorectal cancer cells. Mol Biol Rep, 39, 3675-81.
  11. Hu MD, Xu JC, Fan Y, et al (2012). Hypoxia-inducible factor 1 promoter-induced JAB1 overexpression enhances chemotherapeutic sensitivity of lung cancer cell line A549 in an anoxic environment. Asian Pac J Cancer Prev, 13, 2115-20.
  12. Khuri FR, Herbst RS, Fossella FV (2001). Emerging therapies in non-small-cell lung cancer. Ann Oncol, 12, 739-44.
  13. Li HL, Huang DZ, Deng T, et al (2012). Overexpression of cyclin L2 inhibits growth and enhances chemosensitivity in human gastric cancer cells. Asian Pac J Cancer Prev, 13, 1425-30.
  14. Li LH, He J, Hua D, et al (2011). Lentivirus-mediated inhibition of Med19 suppresses growth of breast cancer cells in vitro. Cancer Chemother Pharmacol, 68, 207-15.
  15. Li XH, Fang DN, Zeng CM (2011). Knockdown of MED19 by short hairpin RNA-mediated gene silencing inhibits pancreatic cancer cell proliferation. Cancer Biother Radiopharm, 26, 495-501.
  16. Malik S, Roeder RG (2005). Dynamic regulation of pol II transcription by the mammalian Mediator complex. Trends Biochem Sci, 30, 256-63.
  17. Mazumder S, Plesca D, Almasan A (2008). Caspase-3 activation is a critical determinant of genotoxic stress-induced apoptosis. Methods Mol Biol, 414, 13-21.
  18. Rosell R, Cecere F, Santarpia M, et al (2006). Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharmacol, 6, 323-31.
  19. Satyanarayana A, Hilton MB, Kaldis P (2008). p21 Inhibits Cdk1 in the absence of Cdk2 to maintain the G1/S phase DNA damage checkpoint. Mol Biol Cell, 19, 65-77.
  20. Snigdha S, Smith ED, Prieto GA, et al (2012). Caspase-3 activation as a bifurcation point between plasticity and cell death. Neurosci Bull, 28, 14-24.
  21. Song W, Jiang R, Zhao CM (2012). Role of integrin-linked kinase in multi-drug resistance of human gastric carcinoma SGC7901/DDP cells. Asian Pac J Cancer Prev, 13, 5619-25.
  22. Sun M, Jiang R, Li JD, et al (2011). MED19 promotes proliferation and tumorigenesis of lung cancer. Mol Cell Biochem, 355, 27-33.
  23. Vojnic E, Mourao A, Seizl M, et al (2011). Structure and VP16 binding of the Mediator Med25 activator interaction domain. Nat Struct Mol Biol, 18, 404-9.
  24. Wang JS, Ji AF, Wan HJ, et al (2012). Gene silencing of $\beta$-catenin by RNAi inhibits proliferation of human esophageal cancer cells by inducing G0/G1 cell cycle arrest. Asian Pac J Cancer Prev, 13, 2527-32.
  25. Wang T, Hao L, Feng Y, et al (2011). Knockdown of MED19 by lentivirus-mediated shRNA in human osteosarcoma cells inhibits cell proliferation by inducing cell cycle arrest in the G0/G1 phase. Oncol Res, 19, 193-201.
  26. Wen H, Feng CC, Ding GX, et al (2013). Med19 promotes bone metastasis and invasiveness of bladder urothelial carcinoma via bone morphogenetic protein 2. Ann Diagn Pathol, 17, 259-64.
  27. Xu LL, Guo SL, Ma SR, et al (2012). Mammalian mediator 19 mediates H1299 lung adenocarcinoma cell clone conformation, growth, and metastasis. Asian Pac J Cancer Prev, 13, 3695-700.
  28. Xu Y, Li C, Tian Q, et al (2012). Suppression of lung cancer metastasis-related protein 1 promotes apoptosis in lung cancer cells. Int J Mol Med, 30, 1481-6.
  29. Yu HG, Wei W, Xia LH, et al (2013). FBW7 upregulation enhances cisplatin cytotoxicity in non-small cell lung cancer cells. Asian Pac J Cancer Prev, 14, 6321-6.
  30. Yu W, Zhang Z, Min D, et al (2014). Mediator of RNA polymerase II transcription subunit 19 promotes osteosarcoma growth and metastasis and associates with prognosis. Eur J Cancer, 50, 1125-36.
  31. Zhang H, Jiang H, Wang W, et al (2012). Expression of Med19 in bladder cancer tissues and its role on bladder cancer cell growth. Urol Oncol, 30, 920-7.
  32. Zhang HQ, He B, Fang N, et al (2013). Autophagy inhibition sensitizes cisplatin cytotoxicity in human gastric cancer cell line SGC7901. Asian Pac J Cancer Prev, 14, 4685-8.
  33. Zhu LJ, Yan WX, Chen ZW, et al (2013). Disruption of Mediator complex subunit 19 (Med19) inhibits cell growth and migration in tongue cancer. World J Surg Oncol, 11, 116.
  34. Zou SW, Ai KX, Wang ZG, et al (2011). The role of Med19 in the proliferation and tumorigenesis of human hepatocellular carcinoma cells. Acta Pharmacol Sin, 32, 354-60.

Cited by

  1. The FOXD3/miR-214/MED19 axis suppresses tumour growth and metastasis in human colorectal cancer vol.115, pp.11, 2016,
  2. Knockdown of Mediator Complex Subunit 19 Suppresses the Growth and Invasion of Prostate Cancer Cells vol.12, pp.1, 2017,
  3. Med19 promotes breast cancer cell proliferation by regulating CBFA2T3/HEB expression vol.24, pp.3, 2017,
  4. Med19 is involved in chemoresistance by mediating autophagy through HMGB1 in breast cancer vol.120, pp.1, 2018,